Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
Clinical trial NCT04146363 · COMPLETED
Trial details
- NCT number
- NCT04146363
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-24
- Primary completion
- 2021-06-21
- Enrollment
- 424
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.